Vanguard Group Inc Krystal Biotech, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,822,888 shares of KRYS stock, worth $405 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,822,888
Previous 2,825,282
0.08%
Holding current value
$405 Million
Previous $509 Million
23.82%
% of portfolio
0.01%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding KRYS
# of Institutions
309Shares Held
24.7MCall Options Held
417KPut Options Held
485K-
Black Rock Inc. New York, NY3.95MShares$567 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.66MShares$382 Million6.67% of portfolio
-
State Street Corp Boston, MA1.36MShares$195 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA942KShares$135 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT923KShares$133 Million9.83% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.69B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...